共 50 条
International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature
被引:410
|作者:
Chun, J
Goetzl, EJ
Hla, T
Igarashi, Y
Lynch, KR
Moolenaar, W
Pyne, S
Tigyi, G
机构:
[1] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[2] Merck Res Labs, La Jolla, CA USA
[3] Univ Connecticut, Dept Physiol, Farmington, CT USA
[4] Hokkaido Univ, Dept Biomembrane & Biofunct Chem, Sapporo, Hokkaido, Japan
[5] Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA
[6] Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands
[7] Univ Strathclyde, Dept Physiol & Pharmacol, Glasgow G1 1XW, Lanark, Scotland
[8] Univ Tennessee, Dept Physiol, Memphis, TN USA
关键词:
D O I:
10.1124/pr.54.2.265
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
The lysophospholipids, lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), are now recognized as important extracellular signaling molecules. These lipid mediators are pleiotropic; among the most common cellular responses are mitogenesis, cell survival (anti-apoptosis), inhibition of adenylyl cyclase and calcium mobilization. Physiologic events associated with these mediators include platelet aggregation, vasopressor activity, wound healing, immune modulation, and angiogenesis. Many of the actions of LPA and S1P are mediated through a set of eight G protein-coupled receptors. Five of these are S1P-prefering while the remaining three are LPA receptors. These receptors are expressed widely and in aggregate signal through a variety of heterotrimeric G proteins. The lysophospholipid receptor family is referred to commonly as the "Edg" group (e.g., Edg-1, Edg-2, etc.). Herein, the molecular pharmacology of the lysophospholipid receptors is reviewed briefly, and a rational nomenclature for LPA and S1P receptors that is consistent with the International Union of Pharmacology guidelines is proposed.
引用
收藏
页码:265 / 269
页数:5
相关论文